Abstracts tagged "TH17 Cells"

Abstract Number: 0068 • ACR Convergence 2024
Enhanced Expression of GPR65 in Inflammatory Sites and Bone Formation Regions in Ankylosing Spondylitis: Evidence from ScRNA-seq Analysis
Yong-Wook Park¹, Ki-Jeong Park², Sungsin Jo³, Tae-Hwan Kim⁴ and Tae-Jong Kim¹, ¹Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ²Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton. T helper 17 (Th17) cells play a pivotal role in the…
Abstract Number: 0081 • ACR Convergence 2024
The Axial Spondyloarthritis Risk Variant CARD9 S12N Enhances Neutrophil-mediated Th Responses
Hillary Struthers¹, Kofi Asare-Konadu², Emily Vance¹ and Ruth Napier³, ¹Oregon Health & Science University, Portland, OR, ²Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, ³Department of Molecular Microbiology and Immunology and Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, VA Portland Health Care System, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the entheses of the spine and/or sacroiliac joints. The cause of axSpA…
Abstract Number: 0873 • ACR Convergence 2024
Epigenetic Control of Pathogenic CD4 T Cell Polarization During Progression to Rheumatoid Arthritis (RA)
Ziyuan He¹, Pravina Venkatesan¹, Adam Savage¹, Marla Glass¹, Lauren Okada², Upaasana Krishnan², Christy Bennett¹, Nhung Tran², Yudong He², Samir Rachid Zaim¹, Padmapriyadarshini Ravisankar², Jessica Garber², Palak Genge², Kevin Lee², Regina Mettey², Cole Phalen², Sugandhika Khosa², Marie Feser³, Fan Zhang⁴, David Boyle⁵, Kristine Kuhn⁴, Kristen Demoruelle⁶, Cate Speake⁷, Jane Buckner⁸, Ananda Goldrath¹, Thomas Bumol⁹, V. Michael Holers¹⁰, Peter Skene¹, Gary Firestein¹¹, Xiaojun Li¹, Kevin Deane¹², Troy Torgerson¹³ and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Institute for Immunology, Seattle, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴University of Colorado, Aurora, CO, ⁵UCSD, La Jolla, CA, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷Benaroya Research Institute at Virginia Mason, Seattle, ⁸Benaroya Research Institute, Seattle, WA, ⁹Allen Institute for Immunology, San Diego, CA, ¹⁰University of Colorado, Denver, CO, ¹¹University of California, San Diego, San Diego, CA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Allen Institute for Immunology, Enumclaw, WA
Background/Purpose: Multiple T cell subsets, including Th1, Th17 cells, and Tfh/Tph, contribute to rheumatoid arthritis (RA) pathology. Clinical trials have shown efficacy of T cell…
Abstract Number: 0878 • ACR Convergence 2024
YY1 a Potential Modulator of IL17/IL23 Axis in Psoriasis Disease
vinod kumar, Tammana Sharma, Rahul Mahajan, Tarun Narang, Sunil Dogra and Sanjeev handa, PGIMER, Chandigarh, Chandigarh, India
Background/Purpose: Psoriasis is an inflammatory skin disease that progresses and worsens if left unattended. IL17 plays a pivotal role as a pathogenic trigger. Despite Th17…
Abstract Number: 0885 • ACR Convergence 2024
Reproducible Single Cell Annotation of Programs Underlying T-cell Subsets, Activation States, and Functions
Dylan Kotliar¹, Michelle Curtis¹, Ryan Agnew¹, Kathryn Weinand¹, Aparna Nathan², Yuriy Baglaenko¹, Yu Zhao¹, Pardis Sabeti³, Deepak Rao⁴ and Soumya Raychaudhuri¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Broad Institute, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Background/Purpose: T-cells play a key role in the pathogenesis of autoimmune disease and in protection against cancer and infection. Consequently, there is widespread interest in…
Abstract Number: 0938 • ACR Convergence 2024
Group 2 Innate Lymphoid Cells Promote T Cell Activation and Development of Autoimmune Arthritis
Agnieszka Lastowska¹, Anders Nguyen², Miriam Bollmann² and Mattias Svensson³, ¹University of Gothenburg, Goteborg, Sweden, ²University of Gothenburg, Göteborg, Sweden, ³University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Innate Lymphoid Cells (ILCs) are the innate counterparts to T cells and can be divided into three functionally distinct subpopulations: Group 1 (ILC1), Group…
Abstract Number: 0947 • ACR Convergence 2024
REX-7117 Is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis
Alexandra Gardino¹, Neil Bifulco¹, Jeremy Hunt², Rishi Vaswani¹, Donglim Park², Patrick Metz², Ksenya Cohen-Katsenelson², Jeong-Ho Kim², Xia Tian², Aryan Alavi², Ajay Nirula², Daniel Treiber², Brian Hodous¹, Seong Kim³ and Paul Smith², ¹Recludix Pharma, Cambridge, MA, ²Recludix Pharma, San Diego, CA, ³Department of Microbiology and Immunology, LSU Health Shreveport, Shreveport, LA
Background/Purpose: Inhibition of JAK family signaling has translated into clinically meaningful efficacy in rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. However, small molecule JAK/TYK2…
Abstract Number: 1790 • ACR Convergence 2024
Response Gene to Complement-32 Expression Is Upregulated in Lupus T Cells and Promotes Th17 Differentiation
Violeta Rus¹, Vinh Nguyen¹, Alexandru Tatomir¹, Cornelia Cudrici² and Horea Rus¹, ¹University of Maryland at Baltimore, Baltimore, MD, ²National Institute of Health, Bethesda, MD
Background/Purpose: RGC (Response Gene to Complement)-32 is a cell cycle regulator expressed in normal tissues, tumors and a variety of cell lines. RGC-32 plays a…
Abstract Number: 1848 • ACR Convergence 2024
Characterization of Treg Phenotype, Function and Its Transcriptome Signatures in Treatment-naïve Rheumatoid Arthritis
Vallayyachari Kommoju¹, Sree Nethra Bulusu², Shruthi S Vembar³, Chengappa Kavadichanda⁴, Molly Thabah⁵, Christina Mary Mariaselvam² and Vir Singh Negi⁶, ¹JIPMER, Pondicherry, India, ²JIPMER, Pondicherry, Puducherry, India, ³IGIB, Bengalore, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ⁶AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Inflammatory cytokines in the periphery can affect Treg stability and function by altering its molecular signatures. We aimed to characterize Treg phenotype, function and…
Abstract Number: 1851 • ACR Convergence 2024
Aberrant Tfh Cells Generated by Th17 Cell Plasticity in the Gut Promote Autoimmune Arthritis
Joyce Wu, The Ohio State University, Columbus, OH
Background/Purpose: Much remains unknown regarding T follicular helper 17 (Tfh17) cells in autoimmunity. We previously showed, and here ask why, egress of gut segmented filamentous…
Abstract Number: 1853 • ACR Convergence 2024
Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome
Leah Huey¹, Emily Vance¹, Kofi Asare-Konadu² and Ruth Napier³, ¹Oregon Health & Science University, Portland, OR, ²Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, ³Department of Molecular Microbiology and Immunology and Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, VA Portland Health Care System, Portland, OR
Background/Purpose: Blau syndrome, a pediatric rheumatological disease characterized by uveitis, arthritis, and dermatitis, is caused by a single point mutation in the gene NOD2. Nod2…
Abstract Number: 1864 • ACR Convergence 2023
Quantifying Inflammation: A Novel In-Vivo Total Body PET Imaging Tool to Determine the Kinetics of the Degree of Changes in Inflammation in Different Time Points
Siba Raychaudhuri¹, Sanchita Raychaudhuri², Naveen Chandrasekar³, Christine Abria³, Sneha Banerjee³, Smriti K Raychaudhuri³ and Abhijit Chaudhari², ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²UC Davis School of Medicine, Sacramento, CA, ³VA Sacramento Medical Center, Mather, CA
Background/Purpose: Collagen‐induced arthritis (CIA) mouse model is one of the best recognized animal model for autoimmune diseases. In this model clinical methods of evaluating inflammation…
Abstract Number: 1929 • ACR Convergence 2023
Anakinra Treatment in Idiopathic Recurrent Pericarditis: A Single-center Experience
Zeynep Toker Dincer¹, Sejla Karup², Erkin Yilmaz¹, Osman Corbali¹ and Serdal Ugurlu¹, ¹Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Idiopathic recurrent pericarditis (IRP) is defined by recurring episodes of pericardial inflammation without a known cause. This study investigates the safety and efficacy of…
Abstract Number: 2442 • ACR Convergence 2023
Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis
Hillary Struthers¹, Emily Vance¹, Kofi Asare-Konadu¹, Holly Rosenzweig² and Ruth Napier¹, ¹Oregon Health & Science University, Portland, OR, ²VA Portland Healthcare System, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) patients have irregular neutrophil responses, as indicated clinically by neutrophilia and increased neutrophil to lymphocyte ratios that positively associate with disease…
Abstract Number: 2571 • ACR Convergence 2023
Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis
Rashmi Thimmapuram¹, Maryam Buni², Huifang Lu³, Jean Tayar⁴, Yuanteng Li⁴, Maria Suarez-Almazor⁵, Rene Rico⁴, Naimah Turner⁴, Roza Nurieva⁴ and Sang Kim⁶, ¹Baylor College of Medicine, Houston, TX, ²MD Anderson Cancer Center, Bellaire, TX, ³UT MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵MD Anderson Cancer Center, Houston, TX, ⁶The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX
Background/Purpose: Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment. However, ICIs often lead to immune-related adverse events (irAEs). Approximately 5% of patients treated with ICIs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].